Author(s)

Shinji Kurosaka, Kazumasa Matsumoto, Akira Irie, Takahiro Hirayama, Morihiro Nishi, Tetsuo Fujita, Takefumi Satoh, Yuichi Sato, Masatsugu Iwamura, Kazunari Yoshida

Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University, Tokyo, Japan.
Department of Urology, School of Medicine, Kitasato University, Tokyo, Japan.

Aims: Inflammatory myofibroblastic tumor (IMT) of the urinary bladder is a clinically and histologically uncommon benign tumor that can be easily mistaken for a malignant neoplasm. We sought to determine whether immunohistochemical staining would be evaluated IMT of the urinary bladder. We have also shown the literatures that imminohistochemical staining of IMT was investigated to distinguish malignant lesions using PubMed data base. Methods: Immunohistochemical staining, including anaplastic lymphoma kinase (ALK), p53, cytokeratin, vimentin, desmin, alpha-smooth muscle actin, myoglobin, smooth muscle myosin and S100, was carried out on serial sections from archival specimens of three patients who underwent transurethral resection and partial cystectomy. Results: Immunohistchemical staining in all patients was positive for ALK and weak positive for p53 protein. In the literatures, positive rates of ALK and p53 inthe IMT of the urinary bladder were 60.9% and 53.1%, respectively. Sarcoma and carcinosarcoma were shown in the pathological specimens with negative ALK and strongly positive p53 inthe same data base. Conclusions: Both ALK and p53 were potentially useful protein markers to distinguish between IMT and sarcoma. However, this study was small sample size. Further study was warranted an investigation of the availability of these proteins in IMT.

Inflammatory Myofibroblastic Tumor; Immunohistochemistry; Bladder Cancer; Anaplastic Lymphoma Kinase; p53

S. Kurosaka, K. Matsumoto, A. Irie, T. Hirayama, M. Nishi, T. Fujita, T. Satoh, Y. Sato, M. Iwamura and K. Yoshida, "Anaplastic Lymphoma Kinase (ALK) and p53 Are Potentially Useful Markers to Distinguish Inflammatory Myofibroblastic Tumor," Open Journal of Urology, Vol. 3 No. 2, 2013, pp. 71-74. doi: 10.4236/oju.2013.32014.